SHPH Overview

Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.

Wall Street analysts forecast SHPH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SHPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Shuttle Pharmaceuticals Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased

Shuttle Pharmaceuticals Holdings Inc. EPS for the last quarter amounts to -1.05 USD, decreased -97.35

Shuttle Pharmaceuticals Holdings Inc (SHPH) has 9 emplpoyees as of March 31 2026.

Today SHPH has the market capitalization of 2.99M USD.